DualityBio Partner Avenzo Therapeutics Presents Positive Preliminary Phase 1 Results for DB-1418/AVZO-1418, a Potentially Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate at 38th EORTC-NCI-AACR Symposium
2026-11-20

·     Pan-tumor potential with responses across six dose levels and five tumor types  (EGFRm NSCLC, UC, CRC, SCCHN, NSCLC-WT)

·        63% ORR in a pretreated EGFRm NSCLC population, the majority of whom were 3rd line or later, multiple responses ≥24 weeks

·        Favorable safety profile demonstrated with low incidence of Grade 3/4 hematologic TEAEs (6% neutrophil count decreased, 4% anemia) at doses up to 5.5 mg/kg every two weeks

·        Avenzo pursuing rapid development plan with global expansion to pursue monotherapy and combinations in multiple tumor types


SHANGHAI, China, November 19, 2026 – Duality Biotherapeutics, Inc. (DualityBio; HKEX: 9606.HK, or the “Company”) today announced that its partner Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, presented positive preliminary clinical data from the Phase 1 portion of the Phase 1/2 AVENTINE-1 study evaluating DB-1418/AVZO-1418, a potentially best-in-class EGFR/HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumors. The data were presented as a poster presentation at the 38th EORTC-NCI-AACR Symposium in Barcelona, Spain, on November 18, 2026, from 12:00 p.m. to 7:00 p.m. CET.

 

Preliminary clinical results for DB-1418/AVZO-1418 are summarized below:


AVENTINE-1 Phase 1/2 Study Background:

As of the October 19, 2026 data cutoff, 61 patients with advanced solid tumors had received AVZO-1418 in the Phase 1 dose-escalation and backfill portion of the Phase 1/2 AVENTINE-1 study at doses of 2 to 6 mg/kg every two weeks (Q2W) or 6 mg/kg every three weeks (Q3W). 

Patients included those with NSCLC-wild-type (NSCLC-WT) (n=20), EGFR-mutant NSCLC (EGFRm NSCLC) (n=19), colorectal cancer (CRC) (n=6), biliary tract cancer (BTC) (n=4), squamous cell carcinoma of the head and neck (SCCHN) (n=4), urothelial cancer (UC) (n=3), and other solid tumors (n=5). The backfill portion of the study was enriched for EGFRm NSCLC based on the strong early efficacy signal. 

All patients (N=61) had received a median of two prior lines of systemic therapy in the advanced or metastatic setting (range, 1–6), with 41% having received two prior lines of systemic therapy and 34% having received three or more prior lines. Overall, 84% of patients had received platinum-based chemotherapy and 54% had received anti-PD-(L)1 immunotherapy. 

Patients with EGFRm NSCLC (n=19) had received a median of two prior lines of systemic therapy in the advanced or metastatic setting (range, 1–4), with 47% having received two prior lines of systemic therapy and 16% having received three or more prior lines. Overall, 58% of these patients had received platinum-based chemotherapy, and all had received a prior third-generation EGFR TKI. At baseline, 63% of patients had an EGFR exon 19 deletion and 32% had an EGFR exon 21 L858R mutation.


Preliminary Safety Results 

The overall safety population included 61 patients, with 48 patients treated at 2 to 5.5 mg/kg Q2W dose levels and 13 treated at 6 mg/kg Q2W and Q3W dose levels.

DB-1418/AVZO-1418 was generally well tolerated in the 2 to 5.5 mg/kg Q2W group (n=48). No dose-limiting toxicities (DLTs) were observed. Treatment-emergent adverse events (TEAEs) reported in more than 20% of patients were predominantly Grade 1 or 2. Anemia and neutrophil count decreased were reported as TEAEs in 33% and 19% of patients, with Grade 3/4 events reported in 4% and 6%, respectively. Prophylactic granulocyte colony-stimulating factor (G-CSF) was not required in the study. The 6 mg/kg Q2W and Q3W doses administered by actual body weight exceeded the maximum tolerated dose (MTD), with two DLTs observed in each cohort.


Preliminary Efficacy Results 

Data are as of the October 19, 2026 cutoff date, with efficacy follow-up through November 5, 2026. Among 48 efficacy-evaluable patients, the objective response rate (ORR) was 38%, including 16 patients with confirmed partial responses (one patient with CRC confirmed their response after the efficacy follow up date), and two patients with unconfirmed partial responses who remained on treatment awaiting confirmatory scans. 26 patients remained on treatment, including 17 of 18 responders, and 13 patients had been on treatment for 24 weeks or longer. 


Responses were observed across six dose levels in five tumor types, including EGFRm NSCLC, NSCLC-WT, UC, CRC and SCCHN, supporting the pan-tumor potential of DB-1418/AVZO-1418. 

A strong efficacy signal was observed in 19 patients with EGFRm NSCLC, majority of whom were previously treated with both a 3rd-generation EGFR TKI and platinum-based chemotherapy. ORR was 63%, including 10 patients with confirmed partial responses and two with unconfirmed partial responses who remained on treatment awaiting confirmatory scans, with multiple responses for 24 weeks or longer. 100% of patients achieved tumor reduction on their first post-baseline scan. As of the data cutoff date, 15 patients remained on treatment.


About DB-1418/AVZO-1418

DB-1418/AVZO-1418 is a potentially best-in-class EGFR/HER3 bispecific ADC in development for locally advanced or metastatic solid tumors. It is designed with higher binding affinity for HER3 than EGFR to enhance delivery of its topoisomerase I inhibitor payload to EGFR/HER3-expressing tumors while limiting effects on healthy tissue. This dual-targeting approach may support activity across multiple tumor types, including EGFRm NSCLC. DB-1418/AVZO-1418 is being evaluated as monotherapy in the Phase 1 portion of the Phase 1/2 AVENTINE-1 study, with combination regimens also planned. Avenzo holds exclusive global rights, excluding Greater China, from DualityBio to develop, manufacture and commercialize AVZO-1418.


About DualityBio

DualityBio is a clinical-stage innovative biopharmaceutical company dedicated to developing next-generation ADCs for patients with cancer and autoimmune diseases. The Company has successfully established multiple next-generation ADC technology platforms with global intellectual property rights. Building on in-depth research into and exploration of disease biology, DualityBio has developed a broad clinical-stage ADC pipeline and is conducting multiple global, multicenter clinical trials across approximately 20 countries, with more than 3,500 patients enrolled. DualityBio has also entered into multiple out-licensing collaborations with global pharmaceutical companies and leading innovative biopharmaceutical companies. As a global engine of ADC innovation, DualityBio continues to develop next-generation ADCs, including bispecific ADCs, ADCs with payloads featuring novel mechanisms of action, and ADCs for autoimmune diseases.

For more information, please visit www.dualitybiologics.com.

Media Contact: PR@dualitybiologics.com

Investor Contact: IR@dualitybiologics.com


Forward-Looking Statements

This press release contains statements that may be deemed to be "forward-looking statements" within the meaning of applicable securities laws. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "aims," "intends," "plans," "believes," "may," and similar expressions. Statements that are not historical facts, including statements about the beliefs, plans, objectives, and expectations of Duality Biotherapeutics, Inc. (the "Company") regarding its business, research and development programs, and product candidates, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to risks related to the Company’s research and development, clinical trials, regulatory approvals, commercialization, and general economic and industry conditions. All information provided in this press release is as of the date of this press release, and the Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law or regulatory rules.